Tuesday, October 20, 2026, 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
October 2017—Seegene presented its Seegene Random Access System at the 69th AACC Annual Clinical Lab Expo in San Diego. The system provides order to report on the same day by simultaneously performing high multiplex real-time PCR testing on a single platform, regardless of specimen type or assays.
October 2017—The Center for Phlebotomy Education has published The Lab Draw Answer Book. The book provides answers to more than 400 questions commonly asked by health care professionals about drawing, handling, and processing blood samples for laboratory tests.
October 2017—BioMérieux announced that BacT/Alert Virtuo, its fully automated blood culture system, has received 510(k) clearance from the FDA and is commercially available in the United States and in countries that recognize the CE mark.
October 2017—Beckman Coulter Diagnostics and partner Diazyme Laboratories announced FDA clearance of a new procalcitonin (PCT) assay for the management of bacterial infections and sepsis.
October 2017—Formulatrix announced the release of its next-generation Constellation Digital PCR System. The digital PCR system mimics contemporary qPCR with a plate-based and high-throughput workflow capable of processing up to four plates per run. For higher throughput applications such as gene expression analysis, plates that accommodate 96 samples will provide partitioning into 8,000 microfluidic chambers per sample.
October 2017—Aim Lab Automation Technologies unveiled at the AACC annual meeting the PathFinder 350D, the latest PathFinder automation platform for decapping and sorting incoming blood collection tubes directly into various analyzer racks ready for analysis.
October 2017—Biocartis Group announced the availability of its Idylla platform in the United States. The Idylla is a fully automated, walkaway, real-time PCR system with a hands-on time of less than two minutes. Its access on-demand design and assay turnaround time of between 90 and 150 minutes allow pathologists to analyze samples at any time, without the need for batching or for trained operators, in virtually any laboratory. The Idylla console and instrument are class II exempt.
October 2017—Siemens Healthineers announced a strategic relationship with Fast-track Diagnostics that includes the addition of FTD’s broad range of CE-marked kits and multisyndromic panels to the menu of Siemens’ Versant kPCR Molecular System.
October 2017—Quidel announced a revised definitive agreement with Alere for its pending acquisition of Alere’s B-type Natriuretic Peptide assay business run on Beckman Coulter analyzers under which post-acquisition, Quidel will undertake direct commercial responsibility for all BNP sales worldwide.
October 2017—The U.S. Preventive Services Task Force posted on Sept. 12 a draft recommendation statement and draft evidence review on screening for cervical cancer. The task force recommends that primary care clinicians screen for cervical cancer in women who are 21–29 years old every three years with cervical cytology. For women ages 30 to 65, screening is recommended with either cervical cytology alone every three years or with high-risk human papilloma virus (hrHPV) testing alone every five years.
